teleo-codex/entities/health/exenatide-pd3-trial.md

type	entity_type	name	domain	status	supports	related	reweave_edges
entity	research_program	Exenatide-PD3 Trial	health	completed	GLP-1 Parkinson's efficacy divergence between lixisenatide Phase 2 success and exenatide Phase 3 failure suggests disease stage and regional CNS penetrance are confounding variables not captured by class-level analysis	Lixisenatide halts motor symptom progression in early Parkinson's disease at 12 months in Phase 2 trial but faces >50% GI side effect rate limiting real-world viability	GLP-1 Parkinson's efficacy divergence between lixisenatide Phase 2 success and exenatide Phase 3 failure suggests disease stage and regional CNS penetrance are confounding variables not captured by class-level analysis|supports|2026-05-09 Lixisenatide halts motor symptom progression in early Parkinson's disease at 12 months in Phase 2 trial but faces >50% GI side effect rate limiting real-world viability|related|2026-05-09

Exenatide-PD3 Trial

Type: Phase 3 randomized controlled trial
Drug: Exenatide (GLP-1 receptor agonist)
Indication: Parkinson's disease (disease-modifying therapy)
Design: Multicenter, double-blind, placebo-controlled, n=194, 96 weeks
Sites: 6 UK research hospitals
Funding: National Institute for Health and Care Research (NIHR)
Primary Endpoint: Movement symptom progression (motor function)
Status: Failed (February 2025)

Overview

Exenatide-PD3 was the largest and longest GLP-1 receptor agonist trial in Parkinson's disease to date. It tested whether exenatide once-weekly could slow disease progression by providing neuroprotection to dopaminergic neurons in the substantia nigra.

Results

Primary endpoint: FAILED — exenatide did not stop movement symptoms from worsening over 96 weeks versus placebo.

Secondary endpoints: FAILED — no benefit in non-motor symptoms (quality of life, cognition, mood) compared to placebo.

DaT-SPECT imaging: No significant change versus placebo. This biomarker tracks dopaminergic neuron degeneration; zero signal indicates no neuroprotection at the structural level.

CSF analysis (mechanistic finding): Only small amounts of exenatide reached the substantia nigra, the brain region affected by Parkinson's. This suggests insufficient CNS penetration to the target region, despite exenatide crossing the blood-brain barrier in other areas.

Context

This trial directly contradicts earlier Phase 2 work (Foltynie group, n=59) which showed significant motor benefit at 9 months (P=0.001). The Phase 3 failure raises questions about:

• Phase 2 selection bias or underpowering
• Regional brain penetrance as the limiting factor (not BBB crossing per se)
• Whether the Phase 2 signal was spurious

Implications

The failure complicates the GLP-1 neuroprotection hypothesis. Two other GLP-1 agonists (semaglutide, liraglutide) remain in ongoing Phase 3 trials for Parkinson's. The CSF finding suggests that different GLP-1 agonists with distinct CNS penetration mechanisms (e.g., semaglutide via albumin binding → tanycytes) may achieve different substantia nigra concentrations and potentially different outcomes.

Expert Response

Dr. Katherine Fletcher (Parkinson's UK): "Really disappointing news" and "a setback." Concerns raised that the failure may impact funding for other GLP-1 trials in Parkinson's.

Timeline

• 2025-02-04 — Phase 3 results published in The Lancet: all endpoints failed, CSF analysis reveals insufficient substantia nigra penetration

References

• The Lancet, February 4, 2025: Exenatide-PD3 Phase 3 Results
• Parkinson's UK press response, February 2025